Journal profile · Rheumatology
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
ISSN 1521-6942 · eISSN 1532-1770 · Bailliere Tindall Ltd · ENGLAND · Bimonthly
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.98; hybrid open access; APC about USD 4,180; median 52 days to acceptance (90 articles, last 24 months); community-reported acceptance: moderate; 54 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY is published by Bailliere Tindall Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research and Spondyloarthritis Studies and Treatments, together about 33.4% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
Browse through a wide range of high-quality academic journals offered by Elsevier, including open access options, to enrich your research journey.
From the journal's Aims & Scope
Research area (LetPub): Rheumatology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Rheumatoid Arthritis Research and TherapiesMedicine15.4%
- Systemic Lupus Erythematosus ResearchMedicine10.5%
- Spondyloarthritis Studies and TreatmentsMedicine7.4%
- Autoimmune and Inflammatory Disorders ResearchMedicine7.1%
- Musculoskeletal pain and rehabilitationMedicine6.8%
- Fibromyalgia and Chronic Fatigue Syndrome ResearchMedicine4.9%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.3%
- Human auditory perception and evaluationEngineering4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.98LetPub ·
- CiteScore 2026-06
- 9.9LetPub ·
- SJR 2026-06
- 1.94LetPub ·
- SNIP 2026-06
- 2.33LetPub ·
- h-index
- 89LetPub ·
- h-index
- 144OpenAlex ·
- i10-index
- 1,349OpenAlex ·
- 2-year mean citedness
- 5.86OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 28.29%LetPub ·
Volume
- Articles per year
- 51LetPub ·
Articles by year OpenAlex count · 2,203 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 56 | 23 | 36 |
| 2025 | 54 | 14 | 297 |
| 2024 | 60 | 31 | 663 |
| 2023 | 71 | 30 | 1,340 |
| 2022 | 54 | 25 | 1,067 |
| 2021 | 51 | 19 | 1,384 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
52 daysMedian, submission to acceptance · P25–P75 36 days – 82 days
- Acceptance to online
- median 15 days (90 articles)
- Submission to online
- median 72 days
- Sample
- 90 articles with submission and acceptance dates (124 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,180 / EUR 3,910 / GBP 3,350 / JPY 518,450 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bailliere Tindall Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1521-6942
- Electronic ISSN
- 1532-1770
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
What CAS zone is BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY in?
In the 2025 upgraded edition of the CAS Journal Ranking, BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY is in Zone 2 of Medicine, and in Zone 3 of the minor category Rheumatology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY?
The latest impact factor listed by LetPub is 6.98; CiteScore 9.9, h-index 144.
How long does peer review take at BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 52 days (interquartile range 36–82 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY?
According to LetPub and DOAJ records, BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY is indexed in SCIE and Scopus.
Is BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY open access, and what is the APC?
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY is a hybrid journal. For open-access publication: APC about USD 4,180.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .